Combretastatin A4 phosphate (CA4P) selectively targets vasculature in animal and human tumors.

被引：0
|
作者：
Rustin, GJS [1 ]
Galbraith, SM [1 ]
Taylor, NJ [1 ]
Maxwell, R [1 ]
Tozer, G [1 ]
Baddeley, H [1 ]
Wilson, I [1 ]
Prise, V [1 ]
机构：
[1] Mt Vernon Hosp, Northwood HA6 2RN, Middx, England
来源：
CLINICAL CANCER RESEARCH | 1999年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
14
引用
收藏
页码：3732S / 3732S
页数：1
相关论文
共 50 条
  • [1] Combretastatin A4 phosphate (CA4P) targets vasculature in animal and human tumours
    Galbraith, SM
    Taylor, NJ
    Maxwell, RJ
    Lodge, M
    Tozer, GM
    Baddeley, H
    Wilson, I
    Prise, VE
    Rustin, GJS
    BRITISH JOURNAL OF CANCER, 2000, 83 : 12 - 12
  • [2] Stimulation of Eryptosis by Combretastatin A4 Phosphate Disodium (CA4P)
    Signoretto, Elena
    Bissinger, Rosi
    Castagna, Michela
    Lang, Florian
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2016, 38 (03) : 969 - 981
  • [3] A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors
    Nathan, P. D.
    Judson, I.
    Padhani, A.
    Harris, A.
    Carden, C. P.
    Smythe, J.
    Collins, D.
    Leach, M.
    Walicke, P.
    Rustin, G. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Phase I pharmacokinetic and toxicity study of weekly intravenous combretastatin A4 phosphate (CA4P).
    Stratford, M
    Folkes, L
    Galbraith, S
    Price, P
    Anderson, H
    Robbins, A
    Sena, L
    Rustin, G
    CLINICAL CANCER RESEARCH, 2000, 6 : 4522S - 4522S
  • [5] Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer
    Nathan, Paul
    Zweifel, Martin
    Padhani, Anwar R.
    Koh, Dow-Mu
    Ng, Matthew
    Collins, David J.
    Harris, Adrian
    Carden, Craig
    Smythe, Jon
    Fisher, Nita
    Taylor, N. Jane
    Stirling, J. James
    Lu, Shiao-Ping
    Leach, Martin O.
    Rustin, Gordon J. S.
    Judson, Ian
    CLINICAL CANCER RESEARCH, 2012, 18 (12) : 3428 - 3439
  • [6] A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)
    Siemann, Dietmar W.
    Chaplin, David J.
    Walicke, Patricia A.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (02) : 189 - 197
  • [7] The effect of combretastatin A4 prodrug (CA4P) on the growth of colorectal liver metastases
    Kuruppu, D
    Muralidharan, V
    Malcontenti-Wilson, C
    Misajon, A
    Skinner, S
    Christophi, C
    O'Brien, PE
    7TH WORLD CONGRESS FOR MICROCIRCULATION, 2001, : 419 - 423
  • [8] Phase II study of combretastatin A4 phosphate (CA4P) in patients with advanced anaplastic thyroid carcinoma (ATC).
    Cooney, M. M.
    Savvides, P.
    Agarwala, S.
    Wang, D.
    Flick, S.
    Bergant, S.
    Bhakta, S.
    Lavertu, P.
    Ortiz, J.
    Remick, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 300S - 300S
  • [9] Phase 1b trial of combretastatin A4 phosphate (CA4P) in combination with radiotherapy (RT): Initial clinical results
    Ng, QS
    Carnell, D
    Milner, J
    Meer, K
    Saunders, MI
    Hoskin, PJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 221S - 221S
  • [10] Vascular targeting activity of combretastatin A-4 phosphate (CA4P) in an ocular model of angiogenesis
    Armstrong, D
    Higa, A
    Iwabuchi, S
    Wood, M
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2002, 43 : U401 - U401
12345